Ch Micronizer'S Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 1.00 M
as on 19-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
as on 19-12-2024
- Revenue 40.74%
(FY 2021)
- Profit 3406.60%
(FY 2021)
- Ebitda 106.11%
(FY 2021)
- Net Worth 133.23%
(FY 2021)
- Total Assets 31.68%
(FY 2021)
About Ch Micronizer'S Pharma
The Corporate was formerly known as Micro Fine Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chintan Pandya and Nayna Pandya serve as directors at the Company.
- CIN/LLPIN
U24232MH2007PTC169466
- Company No.
169466
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ch Micronizer's Pharma Private Limited offer?
Ch Micronizer'S Pharma Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, Common Disease Medicines, Pharmaceutical Tablets, Anti Infective API.
Who are the key members and board of directors at Ch Micronizer'S Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chintan Pandya  | Director | 10-Jul-2020 | Current |
| Nayna Pandya | Director | 15-Nov-2017 | Current |
Financial Performance of Ch Micronizer'S Pharma.
Ch Micronizer'S Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 40.74% increase. The company also saw a substantial improvement in profitability, with a 3406.6% increase in profit. The company's net worth Soared by an impressive increase of 133.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ch Micronizer'S Pharma?
In 2021, Ch Micronizer'S Pharma had a promoter holding of 17.51% and a public holding of 82.49%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 18 Jul 2007 | ₹5.00 M | Satisfied |
How Many Employees Work at Ch Micronizer'S Pharma?
Ch Micronizer'S Pharma has a workforce of 5 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ch Micronizer'S Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ch Micronizer'S Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
